Who
Andrew Guggenhime
President and CFO
Company insider
Files Form 4 as: President and CFO, Vaxcyte; Director, Caribou Biosciences; Director, Metacrine; CFO, Dermira; SVP & CFO, Facet Biotech; SVP & Chief Financial Officer, Pdl Biopharma; Chief Financial Officer, Neoforma.
In numbers
- Trades disclosed
- 305
- Buys
- 0
- Sells
- 40
- Bought
- $0
- Sold
- $22.3M
- Companies
- 7
- Companies where not an officer
- 2
- First trade
- 29 Jul 2005
- Last trade
- 8 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 9 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $432K7,155 at $60.36 | filing |
| 8 Sep 2026filed 9 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $432K7,155 at $60.36 | filing |
| 2 Sep 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $88K1,432 at $61.58 | filing |
| 2 Sep 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $88K1,432 at $61.58 | filing |
| 31 Aug 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $77K1,273 at $60.74 | filing |
| 31 Aug 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $77K1,273 at $60.74 | filing |
| 3 Aug 2026filed 5 Aug 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $54K10,000 at $5.35 | filing |
| 3 Aug 2026filed 5 Aug 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $374K6,956 at $53.76 | filing |
| 3 Aug 2026filed 5 Aug 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $165K3,044 at $54.18 | filing |
| 3 Aug 2026filed 5 Aug 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 3 Aug 2026filed 5 Aug 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 3 Aug 2026filed 5 Aug 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $54K10,000 at $5.35 | filing |
| 3 Aug 2026filed 5 Aug 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $374K6,956 at $53.76 | filing |
| 3 Aug 2026filed 5 Aug 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $165K3,044 at $54.18 | filing |
| 6 Jul 2026filed 6 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $54K10,000 at $5.35 | filing |
| 6 Jul 2026filed 6 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $452K7,913 at $57.16 | filing |
| 6 Jul 2026filed 6 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $121K2,087 at $57.76 | filing |
| 6 Jul 2026filed 6 Jul 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 6 Jul 2026filed 6 Jul 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 6 Jul 2026filed 6 Jul 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $54K10,000 at $5.35 | filing |
News
Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program AdvancesPCVX · rttnews.com · 16 Oct 2026Vaxcyte's (PCVX) Overweight Rating Reaffirmed at Cantor FitzgeraldPCVX · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Andrew Guggenhime; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.